Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Affymax Inc (AFFY)

Affymax Inc (AFFY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Affymax Inc 19200 STEVENS CREEK BOULEVARD SUITE 240 CUPERTINO CA 95014 USA

www.affymax.com P: 650-812-8700

Description:

AFFYMAX INC., is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases and cancer. Affymax's objective is to discover, develop and commercialize novel therapeutics addressing large unmet medical needs. A collaboration of several venture firms created Affymax as an independent company a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs.Their lead product,Hematide, is a synthetic peptide-based erythropoiesis-stimulating agent in clinical development for the treatment of anemia. Hematide is currently entering Phase THREE clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase TWO clinical trials for the treatment of anemia in cancer patients.

Key Statistics

Overview:

Market Capitalization, $K 0
Enterprise Value, $K 0
Shares Outstanding, K 0
Annual Sales, $ 1,370 K
Annual Net Income, $ -14,420 K
EBIT, $ 0 K
EBITDA, $ 0 K
60-Month Beta 5.90
% of Insider Shareholders 1.55%
% of Institutional Shareholders 0.00%
Float, K 0
% Float 0.00%
Short Volume Ratio 1.00

Growth:

1-Year Return -82.93%
3-Year Return -99.53%
5-Year Return -96.96%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 10/01/15
Earnings Per Share ttm 0.00
Annual Dividend Yield 0.00%
Dividend Payable Date 12/23/14
Dividend Payout Ratio 0.00%

AFFY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -1,052.55%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar